Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 1766 | 39.52 |
09:38 ET | 200 | 39.56 |
09:41 ET | 200 | 39.56 |
09:48 ET | 100 | 39.6 |
09:54 ET | 1000 | 39.56 |
09:56 ET | 1000 | 39.63 |
09:57 ET | 800 | 39.705 |
09:59 ET | 600 | 39.78 |
10:03 ET | 2100 | 39.775 |
10:06 ET | 2758 | 39.71 |
10:08 ET | 200 | 39.75 |
10:10 ET | 1000 | 39.67 |
10:14 ET | 1000 | 39.75 |
10:15 ET | 223 | 39.795 |
10:17 ET | 100 | 39.72 |
10:26 ET | 1200 | 39.73 |
10:28 ET | 1000 | 39.72 |
10:30 ET | 600 | 39.735 |
10:35 ET | 400 | 39.62 |
10:44 ET | 100 | 39.69 |
10:46 ET | 400 | 39.68 |
10:48 ET | 800 | 39.64 |
10:50 ET | 100 | 39.66 |
10:51 ET | 5572 | 39.545 |
10:53 ET | 7600 | 39.43 |
11:02 ET | 500 | 39.45 |
11:04 ET | 1066 | 39.51 |
11:06 ET | 100 | 39.465 |
11:09 ET | 1100 | 39.445 |
11:11 ET | 200 | 39.465 |
11:18 ET | 100 | 39.405 |
11:20 ET | 10418 | 39.395 |
11:26 ET | 100 | 39.51 |
11:29 ET | 8092 | 39.225 |
11:33 ET | 1115 | 39.2 |
11:38 ET | 600 | 38.9 |
11:44 ET | 200 | 38.87 |
11:45 ET | 209 | 38.86 |
11:54 ET | 100 | 38.71 |
11:58 ET | 100 | 38.59 |
12:07 ET | 400 | 38.77 |
12:21 ET | 438 | 38.8868 |
12:27 ET | 100 | 38.91 |
12:30 ET | 200 | 38.76 |
12:36 ET | 100 | 38.75 |
12:45 ET | 100 | 38.64 |
12:48 ET | 100 | 38.685 |
12:50 ET | 100 | 38.64 |
12:59 ET | 700 | 38.71 |
01:06 ET | 100 | 38.7275 |
01:10 ET | 200 | 38.835 |
01:17 ET | 300 | 38.77 |
01:21 ET | 200 | 38.74 |
01:24 ET | 600 | 38.75 |
01:28 ET | 200 | 38.73 |
01:32 ET | 300 | 38.81 |
01:35 ET | 100 | 38.94 |
01:37 ET | 850 | 38.83 |
01:39 ET | 200 | 38.71 |
01:44 ET | 310 | 38.76 |
01:46 ET | 100 | 38.78 |
01:48 ET | 495 | 38.825 |
01:55 ET | 200 | 38.81 |
01:57 ET | 1210 | 38.81 |
02:00 ET | 300 | 38.75 |
02:04 ET | 100 | 38.72 |
02:06 ET | 100 | 38.635 |
02:08 ET | 100 | 38.58 |
02:09 ET | 600 | 38.69 |
02:13 ET | 100 | 38.71 |
02:15 ET | 100 | 38.67 |
02:22 ET | 300 | 38.58 |
02:26 ET | 200 | 38.52 |
02:27 ET | 100 | 38.54 |
02:31 ET | 44380 | 38.72 |
02:38 ET | 300 | 38.86 |
02:44 ET | 100 | 38.87 |
02:49 ET | 500 | 38.78 |
02:58 ET | 100 | 38.79 |
03:00 ET | 400 | 38.855 |
03:02 ET | 2900 | 38.89 |
03:05 ET | 100 | 38.91 |
03:09 ET | 100 | 38.895 |
03:12 ET | 400 | 38.935 |
03:14 ET | 400 | 38.895 |
03:16 ET | 600 | 38.905 |
03:18 ET | 1841 | 38.9775 |
03:21 ET | 810 | 38.89 |
03:23 ET | 700 | 38.895 |
03:25 ET | 700 | 38.905 |
03:27 ET | 500 | 38.95 |
03:30 ET | 200 | 38.96 |
03:32 ET | 300 | 38.9 |
03:34 ET | 305 | 38.925 |
03:36 ET | 200 | 38.89 |
03:38 ET | 100 | 38.91 |
03:39 ET | 600 | 38.905 |
03:41 ET | 1700 | 38.915 |
03:43 ET | 9192 | 38.72 |
03:45 ET | 1300 | 38.8 |
03:48 ET | 600 | 38.855 |
03:50 ET | 1100 | 38.831 |
03:52 ET | 1544 | 38.75 |
03:54 ET | 781 | 38.68 |
03:56 ET | 6360 | 38.66 |
03:57 ET | 11644 | 38.5 |
03:59 ET | 31321 | 38.47 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
MoonLake Immunotherapeutics | 2.9B | -50.9x | --- |
Celldex Therapeutics Inc | 2.9B | -16.0x | --- |
SpringWorks Therapeutics Inc | 2.9B | -8.7x | --- |
Iovance Biotherapeutics Inc | 3.0B | -5.9x | --- |
Apogee Therapeutics Inc | 2.8B | -21.0x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.74 |
Book Value | $12.31 |
P/E Ratio | -14.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.